Table 1.
Patient/tumor and treatment factors
| Baseline variables | LDR (n = 104) | HDR (n = 505) | p value | Matched LDR (n = 90) | Matched HDR (n = 90) |
|---|---|---|---|---|---|
| Median age | 49 (27–87) | 50 (23–90) | 0.40 | 50 (28–87) | 49 (26–81) |
| Histology | 0.02 | ||||
| Squamous | 96 (92%) | 437 (86.5%) | 82 (91%) | 79 (88%) | |
| Adenocarcinoma | 4 (4%) | 60 (12%) | 4 (4.5%) | 4 (4%) | |
| Adenosquamous | 4 (4%) | 8 (1.5%) | 4 (4.5%) | 7 (8%) | |
| FIGO stage | <0.001 | ||||
| Ib1 | 4 (4%) | 77 (15%) | 4 (4%) | 9 (10%) | |
| Ib2 | 13(12.5%) | 125 (25%) | 13 (14%) | 16 (18%) | |
| IIa | 0 (0%) | 9 (2%) | 0 (0%) | 3 (3%) | |
| IIb | 45 (43%) | 187 (37%) | 44 (49%) | 35 (39%) | |
| IIIa | 2 (2%) | 8 (1.5%) | 0 (0%) | 0 (0%) | |
| IIIb | 38 (36.5%) | 91 (18%) | 27 (30%) | 27 (30%) | |
| IVa | 2 (2%) | 8 (1.5%) | 2 (2%) | 0 (0%) | |
| Median metabolic tumor volume (cc) | 57 (9–216)a | 34 (1–536)b | <0.001 | Missing data, not matched | Missing data, not matched |
| Median cervix SUVmax | 11 (2.3–36)c | 13 (2.0–60)d | 0.002 | Missing data, not matched | Missing data, not matched |
| PET lymph nodes | 0.49 | ||||
| None | 47 (45%) | 224 (44%) | 42 (46.5%) | 40 (44%) | |
| Pelvic | 47 (45%) | 211 (42%) | 41 (45.5%) | 36 (40%) | |
| Para-aortic | 10 (10%) | 70 (14%) | 7 (8%) | 14 (16%) | |
| Brachytherapy planning | <0.001 | ||||
| 2D | 104 (100%) | 196 (39%) | 90 (100%) | 90 (100%) | |
| 3D CT | 0 (0%) | 51 (10%) | 0 (0%) | 0 (0%) | |
| 3D MRI | 0 (0%) | 258 (51%) | 0 (0%) | 0 (0%) | |
| External beam planning | <0.001 | ||||
| 2D | 104 (100%) | 174 (33%) | 90 (100%) | 90 (100%) | |
| IMRT | 0 (0%) | 331 (67%) | 0 (0%) | 0 (0%) | |
| Chemotherapy | 91 (88%) | 445 (88%) | 0.86 | 78 (87%) | 83 (92%) |
FIGO = International Federation of Gynecology and Obstetrics; HDR = high-dose-rate; LDR = low-dose-rate; IMRT = intensity-modulated radiation therapy.
Incomplete data:
a
N = 37 (36%).
b
N = 357 (71%).
c
N = 57 (55%).
d
N = 425 (84%).